Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05271279 | A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors | terminated | Early Phase 1 | 2 | Beijing Boren HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT04735796 | Study of LM-102 in Subjects in Advanced Tumors | terminated | Phase 1 | 9 | LaNova Medicines LimitedINDUSTRY | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04049617 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors |
| terminated |
| Phase 1 |
| 18 |
| Gilead SciencesINDUSTRY |
| 2 |
| Oct 6, 2022 |
| clinicaltrials |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | terminated | Phase 1 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04959266 | A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | terminated | Phase 1 | 5 | AstraZenecaINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03894540 | Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 22 | IpsenINDUSTRY | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05008913 | Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib(ADME) | terminated | Phase 1 | 2 | AstraZenecaINDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04949425 | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | AstraZenecaINDUSTRY | 2 | Sep 2, 2022 | clinicaltrials |
| NCT03182673 | The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00819221 | AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 2 | Aug 30, 2022 | clinicaltrials |
| NCT01642342 | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | terminated | Phase 1 | 102 | University of Southern CaliforniaOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT01573780 | Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03150056 | Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | terminated | Phase 1 | 73 | GlaxoSmithKlineINDUSTRY | 4 | Aug 10, 2022 | clinicaltrials |
| NCT02700308 | A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases(KYPHO-01) | terminated | Phase 2 | 31 | Centre Leon BerardOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02414724 | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02718404 | 3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors(HIFU-Bone) | terminated | N/A | 12 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 82 | PfizerINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02801097 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)(PAYLOAD) | terminated | Phase 1 | 28 | EpicentRx, Inc.INDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT04009460 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Elpiscience Biopharma, Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03254732 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers | terminated | Phase 1 | 33 | Polaris GroupINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01553071 | Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies | terminated | Phase 1 | 16 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | terminated | Phase 1 | 27 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04156100 | A Study in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 19 | Agenus Inc.INDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | terminated | Phase 1 / Phase 2 | 11 | Incyte CorporationINDUSTRY | 1 | Feb 28, 2022 | clinicaltrials |
| NCT03739138 | Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | terminated | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Feb 28, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01295697 | Study of EZN-2208 Pediatric Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 32 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02687386 | A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR(ECREST) | terminated | Phase 1 | 9 | Dr David ZieglerOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03665129 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors(STELLAR-001) | terminated | Phase 1 | 73 | Innate PharmaINDUSTRY | 2 | Jan 27, 2022 | clinicaltrials |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | terminated | — | 2 | University of PennsylvaniaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05167370 | High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors | terminated | Phase 2 | 2 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT04810208 | Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours | terminated | Phase 1 | 6 | Lidds ABINDUSTRY | 3 | Dec 30, 2021 | clinicaltrials |
| NCT00560716 | A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT02608307 | Medical Treatment Decision Making Using Adaptive Conjoint Analysis | terminated | — | 25 | St. Jude Children's Research HospitalOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02587598 | Study of INCB053914 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 97 | Incyte CorporationINDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT02189174 | Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 3, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT03752177 | A Study of LY3415244 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02840110 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | terminated | — | 22 | Cogent Biosciences, Inc.INDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03403725 | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study(CD205SHUTTLE) | terminated | Phase 1 | 28 | Menarini GroupINDUSTRY | 4 | Sep 28, 2021 | clinicaltrials |
| NCT04111445 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 1 | Adagene IncINDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03471286 | A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT00359294 | A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma | terminated | Phase 1 | 12 | PharmaMarINDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04312282 | The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | terminated | Phase 1 | 93 | Odonate Therapeutics, Inc.INDUSTRY | 1 | Jul 28, 2021 | clinicaltrials |
| NCT02765165 | Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 26 | Proximagen, LLCINDUSTRY | 2 | Jul 23, 2021 | clinicaltrials |
| NCT02168725 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | terminated | Phase 1 | 26 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03804515 | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | terminated | Phase 1 | 2 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 15, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 2, 2022source: clinicaltrials